Currently, In Vitro Diagnostics Quality Control Market is growing at a Compound Annual Growth Rate (CAGR) of 5.3 % to reach USD 1.4 billion by 2026. The rising focus on multi-analyte controls is also expected to offer significant growth opportunities for the market in the coming years. The use of quality control products is, however, not mandatory for all clinical laboratories in many countries. The lack of regulations for these products is expected to adversely affect the market growth.
Request for assumptions & how numbers were triangulated.
https://www.marketsandmarkets.com/requestsampleNew.asp?id=198032582
- Increasing number of accredited clinical laboratories
- Growing adoption of third-party quality controls
- Rising demand for external quality assessment support
- Rising geriatric population and subsequent growth in the prevalence of chronic and infectious diseases
- Rising demand for multi-analyte controls
- Stringent product approval process
- Lack of regulations for clinical laboratory accreditation in several emerging countries
- Lyophilized/freeze-dried Controls
- Trends On Analyte Source: Human Vs. Animal Origin
- Consolidation of Laboratories
Thermo Fisher Scientific, Inc. holds the second position in the global IVD quality control market. The company is a leading provider of IVD quality control products and services. The company offers a robust portfolio of quality controls for clinical chemistry, molecular control, microbiology, serology, serum toxicology testing, specimen validity testing, and therapeutic drug monitoring (TDM). With its strong geographic presence and wide distribution networks, the company has established itself as a leader in the global IVD quality control market. To sustain its leading position and further increase its share in the market, the company focuses on organic and inorganic growth strategies.
Download an Illustrative Overview:
- Recommendations for and approvals of quality control products from the FDA and the College of American Pathologists (CAP)
- Presence of well-established distribution channels and leading companies in the US are driving the IVD quality control market in North America
- In August 2021, Zeptometrix Corporation (US) announced the immediate availability of its ready-to-use NATSARS(COV2)-ERC for laboratory QC and test validation
- In July 2021, Quidel Corporation (US) received the CE Mark for its innovative Savanna multiplex molecular analyzer and Savanna RVP4 Assay (Respiratory Viral Panel-4).
- In June 2021, LGC SeraCare (US) expanded its line of SARS-CoV-2 molecular quality solutions to include AccuPlex SARS-CoV-2 Variant Panel 1.
- In June 2021, Abbott Laboratories (US) received CE mark for its Panbio Rapid Antigen self-test. It helped the company expand its reach throughout Europe for fast, reliable COVID-19 testing